Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

B. Ejlertsen, J. Aldridge, K. V. Nielsen, M. M. Regan, K. L. Henriksen, A. E. Lykkesfeldt, S. Müller, R. D. Gelber, K. N. Price, B. B. Rasmussen, G. Viale, H. Mouridsen

Research output: Contribution to journalArticle

Abstract

Background: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. Patients and methods: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. Results: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio

Original languageEnglish
Pages (from-to)1138-1144
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number5
DOIs
Publication statusPublished - May 2012

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • ERBB2
  • ESR1
  • HER2
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial'. Together they form a unique fingerprint.

  • Cite this

    Ejlertsen, B., Aldridge, J., Nielsen, K. V., Regan, M. M., Henriksen, K. L., Lykkesfeldt, A. E., Müller, S., Gelber, R. D., Price, K. N., Rasmussen, B. B., Viale, G., & Mouridsen, H. (2012). Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Annals of Oncology, 23(5), 1138-1144. https://doi.org/10.1093/annonc/mdr438